ReviewDie Ophthalmologie2026
[Light-induced immunomodulation : Corneal cross-linking to reduce neovascularization and optimize outcomes prior to corneal transplantation].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorneal cross-linking (CXL) is a minimally invasive procedure originally developed to stabilize progressive keratoconus. It is now used in various corneal diseases. In addition to its well-known biomechanical stiffening effect, CXL also demonstrates anti-inflammatory and immunomodulatory properties as well as the ability to induce regression of corneal neovascularization.
objectiveTo summarize and evaluate the biomechanical, antiangiogenic and immunomodulatory effects of CXL and to assess its potential to improve outcomes in high-risk keratoplasty. MATERIAL AND
methodsThe Dresden protocol serves as the foundation of the procedure, using riboflavin-mediated UVA photochemistry to induce cross-linking of stromal collagen. Variations include accelerated, epithelium-on and high fluence protocols, for example in the treatment of corneal neovascularization.
resultsClinical and preclinical data demonstrate long-term stabilization of the cornea in keratoconus, often reducing the need for transplantation. Additionally, peripheral CXL leads to a significant reduction in corneal neovascularization, decreased infiltration of inflammatory cells and downregulation of proangiogenic and lymphangiogenic markers. Experimental studies suggest that performing CXL prior to high-risk keratoplasty can reduce the risk of immunological graft rejection.
conclusionThe use of CXL has evolved from a purely biomechanical treatment into a versatile approach with antiangiogenic and immunomodulatory properties. While initial results are promising, optimal indications, dosages and combination treatment remain the subject of ongoing research.
Indexed as
Identifiers
42257917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.